Literature DB >> 24102012

Treatment of non-small cell lung cancer (NSCLC).

Konstantinos Zarogoulidis1, Paul Zarogoulidis, Kaid Darwiche, Efimia Boutsikou, Nikolaos Machairiotis, Kosmas Tsakiridis, Nikolaos Katsikogiannis, Ioanna Kougioumtzi, Ilias Karapantzos, Haidong Huang, Dionysios Spyratos.   

Abstract

Radical surgery is the standard of care for fit stage I non-small cell lung cancer (NSCLC) patients. Adjuvant treatment should be offered only as part of an investigation trial. Stage II and IIIA adjuvant cisplatin-based chemotherapy remains the gold standard for completely resected NSCLC tumors. Additionally radiotherapy should be offered in patients with N2 lymph nodes. In advanced stage IIIB/IV or inoperable NSCLC pts, a multidisciplinary treatment should be offered consisted of 4 cycles of cisplatin-based chemotherapy plus a 3(rd) generation cytotoxic agent or a cytostatic (anti-EGFR, anti-VEGFR) drug.

Entities:  

Keywords:  Non-small cell lung cancer (NSCLC); lung cancer; targeted treatment; treatment

Year:  2013        PMID： 24102012      PMCID： PMC3791496          DOI： 10.3978/j.issn.2072-1439.2013.07.10

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


  49 in total

1.  Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin.

Authors:  I E Smith; M E O'Brien; D C Talbot; M C Nicolson; J L Mansi; T F Hickish; A Norton; S Ashley
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

2.  Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase.

Authors:  Paolo Ceppi; Marco Volante; Silvia Saviozzi; Ida Rapa; Silvia Novello; Alberto Cambieri; Marco Lo Iacono; Susanna Cappia; Mauro Papotti; Giorgio V Scagliotti
Journal:  Cancer       Date:  2006-10-01       Impact factor: 6.860

3.  Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.

Authors:  C J Langer; M Millenson; E Rosvold; S Litwin; C A McAleer; C A Bonjo; R Ozols
Journal:  Semin Oncol       Date:  1997-08       Impact factor: 4.929

4.  A phase I/II trial of combination paclitaxel and carboplatin in advanced or metastatic non-small cell lung cancer: preliminary results of an ongoing study.

Authors:  R B Natale
Journal:  Semin Oncol       Date:  1995-12       Impact factor: 4.929

5.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Authors:  Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Giorgio Scagliotti; Rafael Rosell; Vincent Miller; Ronald B Natale; Joan H Schiller; Joachim Von Pawel; Anna Pluzanska; Ulrich Gatzemeier; John Grous; Judith S Ochs; Steven D Averbuch; Michael K Wolf; Pamela Rennie; Abderrahim Fandi; David H Johnson
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

6.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

7.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

8.  Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.

Authors:  A J Wozniak; J J Crowley; S P Balcerzak; G R Weiss; C H Spiridonidis; L H Baker; K S Albain; K Kelly; S A Taylor; D R Gandara; R B Livingston
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

9.  A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer.

Authors:  R L Woods; C J Williams; J Levi; J Page; D Bell; M Byrne; Z L Kerestes
Journal:  Br J Cancer       Date:  1990-04       Impact factor: 7.640

10.  Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer.

Authors:  Eftimia Boutsikou; Theodoros Kontakiotis; Paul Zarogoulidis; Kaid Darwiche; Ellada Eleptheriadou; Konstantinos Porpodis; Grammati Galaktidou; Leonidas Sakkas; Wolfgang Hohenforst-Schmidt; Kosmas Tsakiridis; Theodoros Karaiskos; Konstantinos Zarogoulidis
Journal:  Onco Targets Ther       Date:  2013-03-01       Impact factor: 4.147
View more
  113 in total

1.  Prognostic potential of microRNA-138 and its target mRNA PDK1 in sera for patients with non-small cell lung cancer.

Authors:  Lihong Han; Guoxiu Zhang; Nali Zhang; Haiyan Li; Yanyan Liu; Aiguo Fu; Youguang Zheng
Journal:  Med Oncol       Date:  2014-07-27       Impact factor: 3.064

2.  Crosstalk of AP4 and TGFβ receptor signaling in NSCLC.

Authors:  Wei Wang; Xinyu Wu; Yu Tian
Journal:  Tumour Biol       Date:  2014-10-01

3.  microRNA-664 enhances proliferation, migration and invasion of lung cancer cells.

Authors:  Xinhai Zhu; Sheng Ju; Feng Yuan; Guoping Chen; Yue Shu; Chuanchuan Li; Yanhui Xu; Jing Luo; Lilong Xia
Journal:  Exp Ther Med       Date:  2017-05-05       Impact factor: 2.447

4.  European Respiratory Society International Congress best abstract preview from the allied respiratory professionals from assembly 9.

Authors:  Jason Blonshine; Joana Cruz; Andreja Sajnic; Jana De Brandt
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

5.  Activation of FGF receptor signaling promotes invasion of non-small-cell lung cancer.

Authors:  Deping Zhao; Yi Lu; Chenlu Yang; Xiao Zhou; Zhifei Xu
Journal:  Tumour Biol       Date:  2015-01-08

6.  RBPJ inhibition impairs the growth of lung cancer.

Authors:  Qun Lv; Ronglin Shen; Jianjun Wang
Journal:  Tumour Biol       Date:  2015-01-15

7.  miR-143 suppresses the proliferation of NSCLC cells by inhibiting the epidermal growth factor receptor.

Authors:  Hong-Bo Zhang; Li-Chao Sun; Lan Ling; Lu-Hong Cong; Rui Lian
Journal:  Exp Ther Med       Date:  2016-07-27       Impact factor: 2.447

8.  Checkpoint inhibitors in metastatic epidermal growth factor receptor-mutated non-small cell lung cancer patients: where we treating the wrong cancer?

Authors:  Paul Zarogoulidis; Vasilis Papadopoulos; Elena Maragouli; George Papatsibas; Haidong Huang
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

9.  Oral Chinese herbal medicine as maintenance treatment after chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.

Authors:  Q Wang; Q Wang; S F Wang; L J Jiao; R X Zhang; Y Zhong; J Zhang; L Xu
Journal:  Curr Oncol       Date:  2017-08-31       Impact factor: 3.677

10.  Regulation of activating protein-4-associated metastases of non-small cell lung cancer cells by miR-144.

Authors:  Feng Gao; Tao Wang; Zefeng Zhang; Rui Wang; Yang Guo; Junfeng Liu
Journal:  Tumour Biol       Date:  2015-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.